Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro

Chih Hung Hsu, Ming Gao, Chi Long Chen, Pei Yen Yeh, Ann Lii Cheng

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: Epidermoid growth factor receptor (EGFR, HER1) is overexpressed in a majority of head-and-neck cancers, including nasopharyngeal carcinoma (NPC). Although EGFR inhibitors appear to be effective for some head-and-neck cancers, their efficacy in NPC remains unclear. Methods: The effect of EGFR-specific tyrosine kinase inhibitors, including PD153035 and ZD1839, were studied in NPC-TW01, NPC-TW04, and HONE1 cell lines. The effect of combining EGFR inhibitors with cytotoxic agents was evaluated in NPC-TW04 cells. Results: All three NPC cell lines expressed EGFR. PD153035 and ZD1839 inhibited the growth of NPC cells with IC50S around 10 and 20 μM, respectively. These inhibitors, however, effectively suppressed ligand-stimulated EGFR activation in NPC cells with a much lower concentration (≥0.1 μM). The growth-suppression activity of EGFR inhibitors was closely associated with suppression of AKT phosphorylation. LY294002, a phosphatidylinositol-3 kinase (P13K)/AKT inhibitor, did suppress the growth of NPC cells. Pretreatment of EGFR inhibitors by 24 h significantly enhanced the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPC-TW04 cells. Conclusions: Our data indicate that inhibition of EGFR activation is not sufficient to induce growth inhibition in NPC cells in vitro. EGFR inhibitors may be useful adjuncts in treating NPC when combined with conventional anticancer drugs.

Original languageEnglish
Pages (from-to)538-547
Number of pages10
JournalOncology
Volume68
Issue number4-6
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Nasopharyngeal Neoplasms
Growth Factor Receptors
Growth
Head and Neck Neoplasms
In Vitro Techniques
Nasopharyngeal carcinoma
Phosphatidylinositol 3-Kinase
Cell Line
Growth Inhibitors
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Cytotoxins
Protein-Tyrosine Kinases
Doxorubicin

Keywords

  • Chemotherapy
  • Epidermal growth factor receptor
  • Nasopharyngeal carcinoma
  • Phosphatidylinositol-3 kinase/AKT
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. / Hsu, Chih Hung; Gao, Ming; Chen, Chi Long; Yeh, Pei Yen; Cheng, Ann Lii.

In: Oncology, Vol. 68, No. 4-6, 08.2005, p. 538-547.

Research output: Contribution to journalArticle

@article{342035574fe441bc8c018947b2327a12,
title = "Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro",
abstract = "Objective: Epidermoid growth factor receptor (EGFR, HER1) is overexpressed in a majority of head-and-neck cancers, including nasopharyngeal carcinoma (NPC). Although EGFR inhibitors appear to be effective for some head-and-neck cancers, their efficacy in NPC remains unclear. Methods: The effect of EGFR-specific tyrosine kinase inhibitors, including PD153035 and ZD1839, were studied in NPC-TW01, NPC-TW04, and HONE1 cell lines. The effect of combining EGFR inhibitors with cytotoxic agents was evaluated in NPC-TW04 cells. Results: All three NPC cell lines expressed EGFR. PD153035 and ZD1839 inhibited the growth of NPC cells with IC50S around 10 and 20 μM, respectively. These inhibitors, however, effectively suppressed ligand-stimulated EGFR activation in NPC cells with a much lower concentration (≥0.1 μM). The growth-suppression activity of EGFR inhibitors was closely associated with suppression of AKT phosphorylation. LY294002, a phosphatidylinositol-3 kinase (P13K)/AKT inhibitor, did suppress the growth of NPC cells. Pretreatment of EGFR inhibitors by 24 h significantly enhanced the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPC-TW04 cells. Conclusions: Our data indicate that inhibition of EGFR activation is not sufficient to induce growth inhibition in NPC cells in vitro. EGFR inhibitors may be useful adjuncts in treating NPC when combined with conventional anticancer drugs.",
keywords = "Chemotherapy, Epidermal growth factor receptor, Nasopharyngeal carcinoma, Phosphatidylinositol-3 kinase/AKT, Tyrosine kinase inhibitor",
author = "Hsu, {Chih Hung} and Ming Gao and Chen, {Chi Long} and Yeh, {Pei Yen} and Cheng, {Ann Lii}",
year = "2005",
month = "8",
doi = "10.1159/000086998",
language = "English",
volume = "68",
pages = "538--547",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4-6",

}

TY - JOUR

T1 - Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro

AU - Hsu, Chih Hung

AU - Gao, Ming

AU - Chen, Chi Long

AU - Yeh, Pei Yen

AU - Cheng, Ann Lii

PY - 2005/8

Y1 - 2005/8

N2 - Objective: Epidermoid growth factor receptor (EGFR, HER1) is overexpressed in a majority of head-and-neck cancers, including nasopharyngeal carcinoma (NPC). Although EGFR inhibitors appear to be effective for some head-and-neck cancers, their efficacy in NPC remains unclear. Methods: The effect of EGFR-specific tyrosine kinase inhibitors, including PD153035 and ZD1839, were studied in NPC-TW01, NPC-TW04, and HONE1 cell lines. The effect of combining EGFR inhibitors with cytotoxic agents was evaluated in NPC-TW04 cells. Results: All three NPC cell lines expressed EGFR. PD153035 and ZD1839 inhibited the growth of NPC cells with IC50S around 10 and 20 μM, respectively. These inhibitors, however, effectively suppressed ligand-stimulated EGFR activation in NPC cells with a much lower concentration (≥0.1 μM). The growth-suppression activity of EGFR inhibitors was closely associated with suppression of AKT phosphorylation. LY294002, a phosphatidylinositol-3 kinase (P13K)/AKT inhibitor, did suppress the growth of NPC cells. Pretreatment of EGFR inhibitors by 24 h significantly enhanced the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPC-TW04 cells. Conclusions: Our data indicate that inhibition of EGFR activation is not sufficient to induce growth inhibition in NPC cells in vitro. EGFR inhibitors may be useful adjuncts in treating NPC when combined with conventional anticancer drugs.

AB - Objective: Epidermoid growth factor receptor (EGFR, HER1) is overexpressed in a majority of head-and-neck cancers, including nasopharyngeal carcinoma (NPC). Although EGFR inhibitors appear to be effective for some head-and-neck cancers, their efficacy in NPC remains unclear. Methods: The effect of EGFR-specific tyrosine kinase inhibitors, including PD153035 and ZD1839, were studied in NPC-TW01, NPC-TW04, and HONE1 cell lines. The effect of combining EGFR inhibitors with cytotoxic agents was evaluated in NPC-TW04 cells. Results: All three NPC cell lines expressed EGFR. PD153035 and ZD1839 inhibited the growth of NPC cells with IC50S around 10 and 20 μM, respectively. These inhibitors, however, effectively suppressed ligand-stimulated EGFR activation in NPC cells with a much lower concentration (≥0.1 μM). The growth-suppression activity of EGFR inhibitors was closely associated with suppression of AKT phosphorylation. LY294002, a phosphatidylinositol-3 kinase (P13K)/AKT inhibitor, did suppress the growth of NPC cells. Pretreatment of EGFR inhibitors by 24 h significantly enhanced the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPC-TW04 cells. Conclusions: Our data indicate that inhibition of EGFR activation is not sufficient to induce growth inhibition in NPC cells in vitro. EGFR inhibitors may be useful adjuncts in treating NPC when combined with conventional anticancer drugs.

KW - Chemotherapy

KW - Epidermal growth factor receptor

KW - Nasopharyngeal carcinoma

KW - Phosphatidylinositol-3 kinase/AKT

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=23844528811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844528811&partnerID=8YFLogxK

U2 - 10.1159/000086998

DO - 10.1159/000086998

M3 - Article

C2 - 16037687

AN - SCOPUS:23844528811

VL - 68

SP - 538

EP - 547

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4-6

ER -